s/p catalysts:, page-49

3500,

ECQ had a good day today. I suspect that this will be the start of things to come. Forget the biodegradable nappies and baby wipes.

There a few things that I would like to add to your list. The options are trading at a discount not a premium. 1c is the strike on a 2.8c close on the heads and 1.7c on the options.
The options should be 2c on the 2.8c heads, in accounting for the time premium.

The other point is the "seems expensive" to me I think its the complete opposite - I spose that is the way the dice rolls.

If you look at the Wisconsin Alumni Research Foundation and the projects that they are involved in - they are very methodical. The reason Cynata is listing through ecq is to access the capital markets. CDI is listed on the nasdaq and recently raised 40m - their worth 200m.

I expect ECQ to pull a similar gig.

The team from CDI and ISN are both in ECQ. So access to funding will be the key here to progress to stage 2 trials in the near future. I expect management to arrange this with ease. What would happen to ecq if non dilutive funding could be arranged?

Thw WARF is an FDA approved facility. Cynata's stem cell therapy is Allogenic and transferable from patient to patient.

A stand out bio on the asx with brilliant management. 5c plus in on the cards sooner than later imo.